Clene (NASDAQ:CLNN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?

Clene Inc. (NASDAQ:CLNN – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.89 and traded as low as $3.51. Clene shares last traded at $3.66, with a volume of 123,344 shares changing hands.

Analysts Set New Price Targets

A number of research firms have issued reports on CLNN. Wall Street Zen raised Clene from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Clene in a report on Monday, October 19th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Clene currently has an average rating of “Moderate Buy” and an average target price of $34.00.

Get Our Latest Report on CLNN

Clene Trading Up 6.2%

The firm’s fifty day moving average price is $3.88 and its 200-day moving average price is $5.09. The company has a market cap of $49.25 million, a P/E ratio of -1.32 and a beta of 1.04.

Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.50. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.07 million. As a group, research analysts forecast that Clene Inc. will post -1.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Clene stock. State Street Corp boosted its holdings in shares of Clene Inc. (NASDAQ:CLNN – Free Report) by 27.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,901 shares of the company’s stock after buying an additional 8,100 shares during the period. State Street Corp owned about 0.26% of Clene worth $155,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Company Profile

(Get Free Report)

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Recommended Stories

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.